至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Somatic double-hit in MTOR and RPS6 in hemimegalencephaly with intractable epilepsy.

Hum. Mol. Genet.. 2019; 
PelorossoCristiana,WatrinFran?oise,ContiValerio,BuhlerEmmanuelle,GelotAntoinette,YangXiaoxu,MeiDavide,McEvoy-VenneriJennifer,ManentJean-Bernard,CeticaValentina,BallLaurel L,BuccolieroAnna Maria,VinckAntonin,BarbaCarmen,GleesonJoseph G,GuerriniRenzo,RepresaAlf
Products/Services Used Details Operation
PCR Cloning and Subcloning Cloning of RPS6 and mTOR wild type and mutant plasmids All constructs were generated by Genscript (Piscataway, NJ). Get A Quote

摘要

Single germline or somatic activating mutations of mTOR pathway genes are emerging as a major cause of Type II Focal Cortical Dysplasia (FCD), hemimegalencephaly (HME), and Tuberous Sclerosis Complex (TSC). A double hit mechanism, based on a primary germline mutation in one allele and a secondary somatic hit affecting the other allele of the same gene in a small number of cells, has been documented in some patients with TSC or FCD. In a patient with HME, severe intellectual disability, intractable seizures, and hypochromic skin patches, we identified the RPS6 p.R232H variant, present as somatic mosaicism at ~ 15.1% in dysplastic brain tissue and ~ 11% in blood, and the MTOR p.S2215F variant... More

关键词